Page 51«..1020..50515253..6070..»

Category Archives: Regenerative Medicine

Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society…

Posted: November 18, 2019 at 8:46 pm

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced its participation in two upcoming international conferences the MEDICA 2019 International Trade Fair on November 18-21 in Dsseldorf, Germany, and the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting on November 21-22 in Vienna, Austria.

We are excited to showcase our deep and innovative portfolio of osteoarthritis pain management and joint preservation and restoration therapies before the international medical community, said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. We look forward to engaging with medical professionals from across the globe and exploring how our products can enhance their practices.

Anika will showcase its HYALOFAST regenerative therapy and its viscosupplement portfolio, including CINGAL, at the events. Anikas orthopedic therapies are available in more than 65 countries worldwide, and the Company is focused on expanding its portfolio across the joint preservation and restoration continuum of care.

The ICRS Focus Meeting will also feature Anikas HYALOFAST regenerative therapy as part of its surgical skills workshop, a comprehensive wet lab focused on cartilage regeneration and repair procedures.

About MEDICAThe MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The fair takes place once a year in Dusseldorf and is open to trade visitors only. Rising life expectancy, medical progress and the growing awareness of the people for their health are helping to increase the demand for modern treatment methods. This is where the Medica grabs and provides the medical device industry a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The exhibition is divided into the areas of electromedicine and medical technology, information and communication technology, physiotherapy and orthopedic technology, disposables, commodities and consumer goods, laboratory equipment and diagnostic products. Overall, the event draws over 5,000 exhibitors from 65+ countries and 120,000 visitors from over 150 countries.

About ICRSThe ICRS (International Cartilage Regeneration and Joint Preservation Society) is the main forum for international collaboration in cartilaginous tissue research that brings together basic scientists, clinical researchers, physicians and members of industry, engaged or interested in the field of articular biology, its genetic basis and regenerative medicine. It provides continuing education and training to physicians and scientists with an active interest in the prevention and treatment of joint disease to improve patient care through regenerative medicine approaches.

About Anika Therapeutics, Inc.Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Mass. Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The Company has more than two decades of global expertise commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology platform. For more information about Anika, please visit http://www.anikatherapeutics.com.

See original here:
Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society...

Posted in Regenerative Medicine | Comments Off on Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society…

U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa – Ottawa Citizen

Posted: November 18, 2019 at 8:46 pm

Just a few months after Health Canada began cracking down on private clinics offering unapproved stem cell therapies, at least one U.S. clinic has moved in to fill the vacuum with direct marketing to Canadian consumers.

The clinic from Burlington, Vermont, even offers shuttle buses to transport people from Ottawa to the clinic four hours away for treatment it suggests will end joint pain, among other things. Lunch and dinner are free, but each injection costs $6,880. Two for $10,880.

The treatments, using umbilical cord-derived mesenchymal stem cells, are not approved in either Canada or the United States. Health Canada warns that Canadians who travel abroad for stem cell treatments may put themselves at risk.

While stem cells, which were discovered at the University of Toronto in 1961 by James Till and Ernest McCulloch, promise to revolutionize many treatments and could offer breakthroughs for diseases, almost all are still considered experimental and have yet to be proven safe or effective. Clinical trials on numerous potential stem cell therapies are under way, including in Ottawa.

While research progresses, private stem cell clinics have popped up around the world making promises for treatments not yet proven safe or effective.

A 2018 study by Leigh Turner of the University of Minnesota Center for Bioethics found 43 clinics offering stem cell treatments in Canada and 750 in the U.S. Earlier this year, Health Canada sent Canadian clinics, including some in Ottawa, cease-and-desist letters.

Clinics in Vermont, near the Canadian border, appear to have ramped up marketing to Canadians since then. One clinic has been holding back-to-back seminars. Another says it stopped marketing in Canada after receiving a warning from Health Canada.

There have been cases of harm as a result of treatments, including two women who had permanent damage to their sight after stem cells were injected into their eyes at a Florida clinic. Other patients have been infected with unsterilized equipment and others have developed tumours at the site of stem cell injections.

A common harm, critics say, is exploitation.

Dr. Michael Rudnicki is director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute, says of stem cell therapy claims: If it sounds too good to be true, it probably is too good to be true.jpg

Health officials say the clinics are misusing the promise of stem cell therapy to exploit vulnerable patients.

These patients are in pain and they are suffering and they are looking for help and they are being exploited, said Dr. Michael Rudnicki, director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute.

If it sounds too good to be true, it probably is too good to be true.

At a recent seminar at a west-end Ottawa hotel meeting room, Roseanna Ammendolea of the Vermont Center for Regenerative Medicine told a packed room that her clinic and others like it had successfully treated people for pain related to arthritis, neuropathy and other ailments that affected joints using mesenchymal stem cells from umbilical cords. The stem cells, she claimed, are both effective and safe, saying there had been no issues with cell rejection.

We will not give injections if we feel that this injection will not be beneficial to our patients. This is why we are so successful.

Participants, including some who walked with canes and others who talked about being in pain and having mobility issues, were shown videos of people described as Canadian clients who claimed the treatments worked. One man said it was probably the best money I have spent in my life as far as my health. Another said she would do it again in a heartbeat and was able to do things she hadnt been able to do earlier.

They were also shown a slide showing long wait times for hip and knee replacements in Ontario, We are not a priority, she said. Where does that leave us? Participants werent told exactly how the stem cells were supposed to work, but claimed they had successfully improved pain and mobility issues in clients.

What the seminar goers werent told is that, even in the U.S., the treatment is not covered by health insurance because it remains unproven.

The U.S. Federal Drug Administration has issued a warning to consumers not to use cell therapies that are unapproved or unproven.

Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous procedures and confirm whats really being offered before you consider anytreatment, the FDA said in a statement.

The only stem-cell-based products that are FDA-approved for use in the United States are blood-forming stem cells derived from cord blood for limited use in patients with disorders affecting the body system that is involved in the production of blood. Bone marrow is also used for these treatments, but is generally not regulated by the FDA for that use.

Health Canada has granted market authorization for a stem cell therapy to treat graft-versus-host disease and two cell-based gene therapies to treat certain cancers. Most cell therapies are still experimental.

I totally understand the skepticism of it, Doug Argento, who works at the Vermont Center for Regenerative Medicine, said in a telephone interview, but the fact is that things that are approved now and medically paid for were seen as renegade 20 or 30 years ago.

The treatment employs technology developed by Neil Riordan, founder, chairman and chief science officer of the Stem Cell Institute in Panama, using human umbilical cord tissue-derived mesenchymal stem cells. There are 41 such clinics across the U.S. Riordan also played a role in the development of a nutritional product called Stem-Kine, which producers claim without scientific backing increases the number of stem cells circulating in a persons body.

The stem cells injected in the clinic, Argento said, are from umbilical cord tissue as a result of caesarean births to reduce risk of infection.

Rudnicki, of The Ottawa Hospital Research Institute, says there is no evidence that these sorts of cells are regenerative at all. It would not pass muster in Canada.

The public has to understand that there are people out to remove them from their money.

Rudnicki says he regularly receives inquiries from people desperate to get stem cell treatments. He says he tries to connect them with clinical trials that they might be able to participate in.

Rudnicki noted there were multiple clinical trials in Canada, including treatments of autoimmune diseases, trials involving treatment for Type 1 diabetes and others.

But the use of these inappropriate cell types for treating arthritis and joints and so on is certainly not approved by Health Canada and would not be allowed in Canada under the regulations.

There is some evidence that injections of some stem cell products might have a temporary positive impact on inflammation, he said, but it will not be regenerative and will not restore function to joints. They are being sold a bill of goods.

Leigh Turner of the University of Minnesota Center for Bioethics, meanwhile, says the explosion in clinics offering unproven stem cell therapies in the U.S. is a marketplace that traffics in misrepresentation. It is easy to see how people are taken advantage of and scammed.

It is also difficult to find out about physical harms being done to patients.

There are no safety studies. We dont have good data. But we do know there have been some serious harms.

Stem cell therapies have the potential to become standard treatment in some areas, but they are not there yet, Turner said.

Businesses are tapping into genuine human suffering, desperation and also hope.

Turner also noted there was an excellent chance that the vials of liquid being injected into patients did not actually contain stem cells.

Dr. Jonathan Fenton of another stem cell clinic in Burlington, the Vermont Regenerative Medicine, said he had complained about the new clinic, the Vermont Center for Regenerative Medicine, which has a similar name and employs hard-sell tactics, he said.

His clinic takes bone marrow from patients hips and injects it. The procedure is done the same day. He says he regularly sees Canadian patients for bone marrow aspiration therapy and platelet-rich plasma treatments, using their own blood. The treatments, he says, speed healing and are allowed in the U.S. The use of bone marrow aspiration is neither proven nor allowed in Canada.

Fenton, who is secretary-treasurer of the American Academy of Orthopedic Medicine, acknowledged many people offering stem cell treatments are not doing it to the highest ethical standards.

He has filed complaints with state officials over clinics selling unsafe or fraudulent treatments. I have asked the state and federal judiciary to close down this clinic for committing fraud.

He said his platelet and bone marrow treatments were covered by a major Vermont health insurer because they saw the cost of benefits were going down and patients were requiring fewer surgeries.

He said he was told by Health Canada that he could not market in Canada. Representatives of the Vermont Center for Regenerative Medicine, meanwhile, said they had discussions with Health Canada about what they could and could not say when marketing in Canada before holding seminars in Ottawa and Halifax.

We have looked at the information provided and have not identified any immediate non-compliance with advertising regulations pertaining to Canadian health products, a Health Canada spokesperson said, adding that the agency was continuing to assess.

Back at a west-end Ottawa hotel, some participants in the seminar, including a retired pharmacist, said they were considering getting the treatments. But its expensive.

Another participant said he was skeptical. They seemed very sketchy when I went online.

epayne@postmedia.com

ALSO IN THE NEWS

Hoffman and Kaushic: Were losing the fight against superbugs

Super-agers, who live to at least 110, boast stronger immune systems, helping them fight off diseases

Spinal-cord stimulator really promising: Survivor moves legs for first time since Humboldt bus crash

Go here to see the original:
U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa - Ottawa Citizen

Posted in Regenerative Medicine | Comments Off on U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa – Ottawa Citizen

Innovative cell therapy research boosted by state funds – AroundtheO

Posted: November 18, 2019 at 8:46 pm

An innovative new research project from UOs Robert Guldberg has captured the attention of Oregons economic development agency Business Oregon and the UOs Office of the Vice President for Research and Innovation.

Guldbergs $1.2 million project, which zeroes in on one of the central challenges of the fast-growing cell therapy industry, is the first to tap into the University Innovation Research Fund. The new state fund is designed to support research at Oregon universities that drives innovation and economic development.

The manufacturing sector around cell therapy repair or replacement of tissues such as bone, cartilage, blood vessels and skin is a rapidly growing biomedical market. Guldbergs project, which is co-funded by the Department of Defense, could help make Oregon a player in a sector that is projected to be worth $8 billion to $10 billion within the next decade.

Cell therapy has potential applications for everything from treating cancers to repairing spinal cord injuries to improving weakened immune systems. But one of the limitations of current methods of manufacturing is the high cost and variability of using animal-based culture media, Guldberg says.

The standardized media that Guldberg and his collaborators are seeking to develop could help accelerate the development and manufacturing of regenerative medicine products.

The impact of this project will be to develop and validate chemically defined and animal-free culture media that cost-effectively meets cell manufacturing industry standards and needs, said Guldberg, vice president and Robert and Leona DeArmond Executive Director of the Phil and Penny Knight Campus for Accelerating Scientific Impact. This project could help enable greater availability of new cell therapies to more patients and for a broader range of clinical applications.

Department of Defense funding for the project comes through the Medical Technology Enterprise Consortium supported by the U.S. Army Medical Research and Material Command program and in partnership with RegenMed Development Organization.

Not only does this research promise to lead to novel therapeutic treatments for patients but it will also open new doors for engagement with industry partners and the Department of Defense for UO researchers but also for other state research universities and biotechnology enterprises, said David Conover, vice president for research and innovation.

Conover stressed the collaborative elements that gave rise to the University Innovation Research Fund, which represents a unique partnership between Oregon universities and Business Oregon. Working with the states business development agency, he and other senior research officers from Oregons public universities successfully advocated for a state fund that would help attract more federal funds to support economic development.

We made the case before the state Legislature and they came through with the funding, Conover said. Its a real triumph and proof that our public universities can work together to achieve benefits for the state of Oregon.

State Rep. Dan Rayfield, a Corvallis Democrat and co-chair of the Joint Committee on Ways and Means, said he was proud to support the passage of the fund.

We know that Oregons research universities are frequently competing for federal grants that could contribute to the states well-being, but often they require nonfederal funding as a match, Rayfield said. This fund is a way for the state to show our commitment to innovation and economic development, and Im excited about this first project and many more to come. Its going to have a big return on investment for Oregon.

Projects supported by the innovation fund not only must fuel innovation and commercialization of technology from Oregons public universities but must also align with priority industries, such as advanced manufacturing, high technology, outdoor gear and apparel, health care innovation, food and beverage, and forestry and wood products. Guldbergs project checked several of these boxes, said Chris Harder, director of Business Oregon.

The state of Oregon strongly supports innovation at our states universities and we see great potential in Dr. Guldbergs groundbreaking research in the rapidly growing field of cell therapy manufacturing, Harder said. This award and the collaborative project behind it shows the potential we have to grow biotechnology industries in Oregon.

An internationally renowned researcher and entrepreneur in the regenerative medicine field, Guldberg is well-positioned to lead the states efforts to expand its cell manufacturing sector. He has co-founded five companies and is the past president of the Tissue Engineering and Regenerative Medicine International Society Americas Chapter.

Before arriving at the UO from Georgia Tech to lead the Knight Campus, Guldberg helped lead a successful application to the National Science Foundation to establish a Center for Cell Manufacturing Technologies and participated in the development of a national roadmap for cell manufacturing in partnership with federal agencies, several universities and numerous biotech companies, including several companies with a presence in Oregon.

The project has already amassed a long list of industry collaborators and is expected to attract more interest moving forward as new partnerships are established through the Medical Technology Enterprise Consortium.

Through participating in these consortia, Oregon has the opportunity to tap into investment from these industry partners as well as create new technologies with the potential to lead to new start-up companies, Guldberg said.

Another benefit of participation, Guldberg says, is the training of Oregon students in a rapidly growing field and therefore job creation. Cost share on the project will fund three undergraduate scholars to help fulfill the scope of work but also provide them with experiential training and mentorship from senior staff scientists.

Kate Petcosky-Kulkarni, UOs director of strategic research initiatives, is hopeful other researchers will follow Guldbergs lead and apply for matching funding through the University Innovation Research Fund.

The program creates a new research opportunity that wasnt there a year ago, Petcosky-Kulkarni said. It effectively ups the ante and allows faculty to apply for funds that they might not otherwise pursue due to high match requirements.

UO researchers interested in applying for matching funds through the University Innovation Research Fund can find more information online. Potential applicants are required to contact Research Development Services at rds@uoregon.edu to discuss the project before preparing the application materials to confirm alignment with project goals.

By Lewis Taylor, University Communications

Visit link:
Innovative cell therapy research boosted by state funds - AroundtheO

Posted in Regenerative Medicine | Comments Off on Innovative cell therapy research boosted by state funds – AroundtheO

Regenerative Medicine Market Overview, Segment Analysis, Growth Drivers and Forecast to 2024 – Downey Magazine

Posted: November 18, 2019 at 8:46 pm

The global regenerative medicine market is expected to witness significant growth during the forecast period (20172023), due to the increase in the prevalence of chronic diseases, orthopaedic injuries, genetic disorders, growing aging population, increasing government funding along with the private funding in the research & development of regenerative medicines with the advancement in nanotechnology based drug delivery system, and moderate healthcare reforms. Currently, major breakthrough in the area is the development of tissue engineered trachea, transplantation of retinal pigment differentiated by stem cell based therapy to treat age-related macular degeneration. However, recently research labs have started to focus on regenerating solid organs such as heart, kidney, lungs and other organs to curb the problems associated with organ transplantation.

Orthopaedic and musculoskeletal disorders, dermatology, cardiology, oncology, diabetes, and central nervous system diseases are the key application areas of regenerative medicine. Orthopaedic and musculoskeletal disorders was the largest application in the global market in 2016, due to the high incidence of accidents and injuries registered, and its application as therapeutic approach to congenital disorders. Oncology is expected to be fastest growing application in the global market, due to the rise in prevalence of cancer cases globally.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/regenerative-medicine-market/report-sample

Technological innovations in the area of stem cell therapy and tissue engineering has led to rapid growth of the regenerative medicine market size. The key factors which drive the growth of the global market include increase in the demand of orthopaedic surgeries, government healthcare reforms in certain countries such as the U.S. and Canada, aging population, rise in chronic diseases, increasing prevalence of bone and joint diseases, and innovations in nanotechnology that aids in drug delivery mechanism.

Globally, North America is the largest market for regenerative medicine followed by Europe. The largest regenerative medicine market size of North America is attributed to the high rate of incidence of cardiac disorders, autoimmune diseases, and increasing prevalence of cancer patients among the American population. Additionally, the involvement of government organization for funding in the area of R&D of regenerative medicines, technological advancement and other policies are driving the growth of the North American market.

MARKET SEGMENTATION

By Type

By Therapy

Read more: https://www.psmarketresearch.com/market-analysis/regenerative-medicine-market

By Application

Follow this link:
Regenerative Medicine Market Overview, Segment Analysis, Growth Drivers and Forecast to 2024 - Downey Magazine

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine Market Overview, Segment Analysis, Growth Drivers and Forecast to 2024 – Downey Magazine

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN4001 for Treatment of Heart Failure at…

Posted: November 18, 2019 at 8:46 pm

GERMANTOWN, Md., Nov. 18, 2019 /PRNewswire/ --Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday presented preliminary data from the Phase I trial (clinical trial identifier: NCT03409627) of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, in a poster at the American Heart Association (AHA) Annual Meeting.1 On November 7, 2019, Triple-Gene announcedthat enrollment in this Phase I study has been completed.

"We are pleased to have had the opportunity to share our early clinical data from this first-in-human study with the cardiology community at this prestigious meeting," stated Thomas D. Reed, PhD, Co-founder and Managing Director of Triple-Gene. "The data presented yesterday suggest that the combination of our transiently expressed, non-integrating naked plasmid DNA with the focused cardiac delivery enabled by Retrograde Coronary Sinus Infusion (RCSI) has the potential to open a new biologics treatment paradigm for treating cardiovascular diseases."

Triple-Gene's investigational therapy uses non-viral delivery of a constitutively controlled multigenic plasmid designed to express human S100A1, SDF-1, and VEGF165 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively, and target the underlying molecular mechanisms of pathological myocardial remodeling. The plasmid therapy is delivered via RCSI, which allows for cardiac-specific delivery to the ventricle.

Dr. David Bull, who was the first investigator to dose a patient with INXN-4001, stated, "Having carefully reviewed the science behind Triple-Gene's product candidate, I was very excited to initiate the INXN4001 clinical trial at the University of Arizona. Heart failure is a devastating disease, and my patients on Left Ventricular Assist Devices (LVAD) have very few therapeutic treatment options. Triple-Gene's novel triple-effector plasmid, as delivered by the minimally invasive RCSI procedure, represents a potential game-changing approach for addressing disease pathology in this high-risk patient population."

Amit N. Patel, MD, MS, Co-founder and Clinical Director of Triple-Gene added, "We are pleased to have completed dosing of the twelve patients in this clinical trial between our two clinical sites at the University of Arizona, Tucson, AZ and The Christ Hospital, Cincinnati, OH, and look forward to sharing additional data for this investigational therapy once the trial is complete. Based upon the promising early results to date, we are now exploring clinical trial designs that contemplate repeat dosing as well as additional orphan-like heart failure subtypes."

1Jaruga-Killeen E, Bull DA, Lotun K, Henry T, Egnaczyk G, Reed TD and Patel AN. Safety of first-in-human triple gene therapy for heart failure patients. Presented at the American Heart Association Annual Meeting, November 17, 2019.

About Triple-GeneTriple-Gene LLC is a clinical stage gene therapy company focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of complex cardiovascular diseases. The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure. Triple-Gene is a majority owned subsidiary of Intrexon Corporation(NASDAQ: XON) co-founded by Amit Patel, MD, MS, and Thomas D. Reed, PhD, Founder and Chief Science Officer of Intrexon. Learn more about Triple-Gene at http://www.3GTx.com.

About Intrexon CorporationIntrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNAto create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more at http://www.dna.comor follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.

TrademarksIntrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Investor Contact:

Steven Harasym

Vice President, Investor Relations

Intrexon Corporation

Tel: +1 (301) 556-9850

investors@dna.com

Corporate Contact:

Marie Rossi, PhD

Vice President, Communications

Intrexon Corporation

Tel: +1 (301) 556-9850

publicrelations@dna.com

SOURCE Triple-Gene LLC

https://3gtx.com

View original post here:
Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN4001 for Treatment of Heart Failure at...

Posted in Regenerative Medicine | Comments Off on Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN4001 for Treatment of Heart Failure at…

Future Success of Regenerative Medicine Market Growth and Forecasting with Top Key Players like Acelity LP, Nuvasive, Vericel Corporation Osiris…

Posted: November 18, 2019 at 8:46 pm

The global regenerative medicine market size was estimated at USD +2 million in 2019 and is expected to witness a CAGR of +11% throughout the forecast period.

Regenerative Medicine can be defined as a process of replenishing or regenerating human cells, tissues or organs to restore or establish a normal function. This area contains a commitment to regenerate damaged tissues and organs by replacing damaged tissue or by encouraging the bodys own repair mechanisms to heal tissues or organs. Regenerative medicine may enable scientists to grow tissues and organs in the laboratory and implant them safely when the body cannot cure itself.

Request for Sample@

https://www.reportconsultant.com/request_sample.php?id=42636

Current estimates indicate that around one in three Americans could benefit from regenerative medicine. Regenerative Medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells. Examples include cell therapies (injection of stem cells or progenitor cells); immune therapy and tissue engineering.

Top Key Players:-

Application:

Ask for Discount@

https://www.reportconsultant.com/ask_for_discount.php?id=42636

North America, Latin America, Middle East, Africa, and Europe have been inspected to get a portfolio of the Global Regenerative Medicine Market. According to Report Consultant, the global market is expected to grow in the forecast period. The market has been elucidated with different case studies as well as feedback from various professionals. With respect to different attributes such as Importance, Development in the global market has explained in an accurate and professional manner. The progress projections for different market segments are also highlighted in the research report.

Table of content:-

Enquiry before buying@

https://www.reportconsultant.com/enquiry_before_buying.php?id=42636

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative businesses in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered businesses all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the global futuristic market.

Contact us:

Rebecca Parker

(Report Consultant)

Overland Park,

United States

Contact No: +1 620-220-2270

sales@reportconsultant.com

http://www.reportconsultant.com

See the rest here:
Future Success of Regenerative Medicine Market Growth and Forecasting with Top Key Players like Acelity LP, Nuvasive, Vericel Corporation Osiris...

Posted in Regenerative Medicine | Comments Off on Future Success of Regenerative Medicine Market Growth and Forecasting with Top Key Players like Acelity LP, Nuvasive, Vericel Corporation Osiris…

David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit – Benzinga

Posted: November 18, 2019 at 8:46 pm

New Orleans, LA, November 18, 2019 --(PR.com)-- David Crais, CEO of CMG Carealytics, was invited to the 4th Cross-Industry Innovation Summit held at Johnson Space Center in Houston, Texas last week. An exclusive group of Chief Innovation Officers from NASA, the US Navy, Army, Columbia University Business School, Barnard College, Amazon, Google, Dow Jones, and other global organizations.

Held over three days last week at Johnson Space Center, the Cross Industry Innovation Summit is a deep dive into innovation theory and practice from venture capital, startups, and technology transfer to corporate innovation labs and research and development programs. Exploring the discovery and investigative process with manufacturing, development, and commercialization and adoption of emerging technologies, new ideas, and new program development, these business, social, and government leaders work hands on to share ideas and cultural outlook and framework to bring about advances to their domains and constituencies . This is the fourth year of the program and the fourth year David Crais was asked to participate.

CMG Carealytics, a product management and development firm specializing in scientific, medical, and complex systems and industries, is known as a leader in the innovation and commercialization field. Working with incubators, accelerators, R&D teams, tech parks, venture capital firms, and expert networks, CMG Carealytics founded and led by David Crais continues to spearhead new innovation methods and practices in quality engineering, agile, scrum, lean, buisness analysis, product management, and other sociotechnical methods and in technologies from biotech, regenerative medicine, medical device, digital medicine, personalized medicine, printed electronics, imaging, thermography, and other technologies.

Crais has been engaged in innovation theory since his university education in scientific history and social change up to his development of medical technologies and taking them to market as publicly traded companies, private placements, new product launches, non-profits, and with economic development initiatives.

His participation in the Cross-Industry Summit with NASA is in addition to his work in serving on the Master Plan Task Force with Stennis Space Center in Mississippi, as a board member on the LSU Stephenson Entrepreneurship Institute, an advisor to Nevada State College Entrepreneurship Program, UC Irvine Medical Technology Commercialization Program, and with organizations like the Urban Land Institute, Angel Capital Association, Association for Corporate Growth, and other roles.

Contact Information:CMG CarealtyicsDavid Crais773-398-4143Contact via Emailcraisgroup.comghartman1@hotmail.com

Read the full story here: https://www.pr.com/press-release/799655

Press Release Distributed by PR.com

Go here to read the rest:
David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit - Benzinga

Posted in Regenerative Medicine | Comments Off on David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit – Benzinga

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024 – PRNewswire

Posted: November 18, 2019 at 8:46 pm

NEW YORK, Nov. 18, 2019 /PRNewswire/ --

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.

Read the full report: https://www.reportlinker.com/p05827567/?utm_source=PRN

The major drivers contributing to the growth of the global cell and gene therapy market are the growing incidence of several chronic and terminal diseases, including cancer, the launch of new products, the increasing availability in clinical evidences of these products in terms of safety and efficacy, the rapid adoption of CAR T-cell therapy, favorable regulatory support in the development of these treatment, and improved manufacturing expertise in these products.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period: Increased Pool of Patient Population with Several Ailments Favorable Regulatory Support and Increasing Special Designations for Cell and Gene Therapy Products Growing Demand for CAR T-cell Therapy Products Increasing Strategic Acquisition Activities

The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2018?2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.

Cell and Gene Therapy Market: Segmentation

This research report includes detailed market segmentation by product, application, end-user, and geography. The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments. The segment is likely to witness upward growth on account of expanded expertise in the manufacturing of stem cell-based products.

The gene therapy segment is expected to witness faster growth as the penetration of these products is increasing at a significant rate, especially in developed economies. The market is expected to grow during the forecast period due to the increased patient base for the existing gene remedy products, expected the launch of other gene therapy-based products for several indications, and expanded indication approvals for existing commercially available products.

The oncology segment accounts for the highest share of the global market. The growth of the oncology segment is increasing at a fast rate on account of the growing prevalence of several types of cancers. Currently, the available products not only modify the disease but also improve the quality of the patient's life, thereby decreasing the mortality rate. The market in the dermatology segment is increasing at a steady rate. This segment owns its growth to the increasing incidence and prevalence rate of several types of wounds, which are difficult to treat under normal conditions and the launch of innovative products. The dermatology segment is likely to showcase growth due to the high product availability of wound care products in the market.Hospitals are the leading end-user segment. The segment is growing mainly due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic wound on account of diabetes feet, pressure ulcers, and other injuries.

Market Segmentation by Products Cell Therapy Gene TherapyMarket Segmentation by Distribution Channel Type Oncology Dermatology Musculoskeletal OthersMarket Segmentation by End-users Hospitals Wound Care Centers Cancer Care Centers Ambulatory Surgical Centers Others

Geographical Insights

The US market dominates the cell and gene therapy market in North America due to the high prevalence of chronic diseases and other conditions, which require these treatment methods. There is also comparably high utilization and wide accessibility of these therapies. The oncology segment is likely to witness significant growth in North America.The market in Europe is expected to witness upward growth in the near future on account of the growing prevalence of chronic diseases and rising elderly population. In Europe, cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally.

Market Segmentation by Geography North Americao USo Canada APACo Japano Chinao South Koreao Australia Europeo Germanyo Franceo UKo Spaino Italy Latin Americao Brazilo Mexico MEAo Turkeyo Saudi Arabiao UAE

Key Vendor AnalysisThe global market is characterized by the presence of a few global, large-scale companies and several small to medium-scale companies offering one or two cell and gene therapy products. Global players are majorly offering innovative products with the potential of disease-modifying characteristics that are generating significant revenues, especially in Europe and US regions. Most innovative and breakthrough products are approved in the European countries and the US. Vendors are targeting mostly developed economies such as the US, Germany, France, the UK, Spain, and Japan as the uptake of these products is higher in these countries than low and middle-income countries. However, the market in these regions is at the nascent stage.

Key Vendors Gilead Sciences Spark Therapeutics Novartis AG Organogenesis Amgen Osiris Therapeutics Dendreon Vericel

Other Prominent Vendors Anterogen Tego Sciences Japan Tissue Engineering JCR Pharmaceuticals Medipost MolMed AVITA Medical CollPlant Corestem Biosolution Stempeutics Research Orchard Therapeutics Takeda Pharmaceutical Company CHIESI Farmaceutici CO.DON AnGes GC Pharma JW CreaGene APAC Biotech Nipro Corp. Terumo Orthocell bluebird bio

Key Market InsightsThe report provides the following insights into the market for the forecast period 20192024. Offers sizing and growth prospects of the market for the forecast period 20192024. Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market. Includes a detailed analysis of growth drivers, challenges, and investment opportunities. Delivers a complete overview of segments and the regional outlook of the market. Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain a competitive advantage.

Read the full report: https://www.reportlinker.com/p05827567/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read more from the original source:
The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024 - PRNewswire

Posted in Regenerative Medicine | Comments Off on The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024 – PRNewswire

4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress held by MarketsandMarkets – ccsentinel.com

Posted: November 18, 2019 at 8:46 pm

Date: 10th 11th March 2020 Location: London UK

In the 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine, we would be focusing on the pre-clinical, manufacturing, clinical and regulatory aspects of cell therapies and regenerative medicine. This Congress event will be held on 10th and 11th March 2020 in London -UK

Regenerative therapies are proving its acceptance in the potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide an illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.

Get Register and Download the Agenda at https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/

Key Pointers 4th Annual MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress

Conference Registration

Lets get you sorted! Choose which applies best to you @ https://www.reportsnreports.com/events/4th-annual-marketsandmarkets-bioprocessing-of-advanced-cellular-therapies-regenerative-medicine-congress/register

Read the original:
4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress held by MarketsandMarkets - ccsentinel.com

Posted in Regenerative Medicine | Comments Off on 4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress held by MarketsandMarkets – ccsentinel.com

I Got Fillers to Fix the Bump on My Noseand It Was Bizarre and Incredible – Prevention.com

Posted: November 18, 2019 at 8:46 pm

I am my own harshest critic when it comes to my physical flaws. I dont think thats uncommonwe all see parts of ourselves that others are blind to. My large, hooked nose has always bothered me. While Ive learned to appreciate its size, Ive never grown fond of the large bump. Additionally, at the ripe young age of 28, I have significantly more forehead wrinkles than anyone else my age. Yes, I wear sunscreen, but Im also a very expressive person, particularly when it comes to my eyebrows. My expressiveness has also manifested in prominent crow's feet.

While Im not opposed to aging and think wrinkles and crow's feet are attractive, its bizarre how many I have considering Im still in my twenties. I also know these things only get worse over time. I will say without shame that I dont want to have a withered and leathered face by the time Im 40. Because of this, I decided to make an appointment with Dr. Jessie Cheung, a board-certified dermatologist specializing in aesthetics, hormones and sexual health, and regenerative medicine.

When I arrived for my appointment, Dr. Cheung warmly greeted me, her face glowing like a cherub. She ushered me into her office and asked what Id like to get done. Its a bizarre question, when you think about it. The essence of what she was asking was: How can I change your face?

After explaining that Id like to get rid of my wrinkles and maybe add a little lip for fun (I have zero upper lip), she said she could do that without a problem. Then, she asked if she could make a few suggestions. This was the moment that I learned I'm actually not my own harshest critic.

It turns out, the left side of my chin is larger than the right side. My cheekbones have sunken in and my jawline could be stronger. There was more, but Ill save you from hearing it all.

Its wild: Ive looked at my face tens of thousands of times and had never noticed these things. Even when she pointed them out, I didnt really see them. Dr. Cheung then said that with a few fillers, she could straighten the bump on my noseit sounded too good to be true.

After all of her suggestions, I had a bit of an internal panic attack. It wasnt because I was becoming more aware of my flaws or, perhaps we should say, the areas of my face that could be improved upon. It was more that I was worried that my face would look completely different and I like my face. I didnt want someone elses face. I wanted mine, just a little smoother.

So, I expressed my reservation and repeatedly asked if all this work would look natural. Clearly, I wasnt the first person Dr. Cheung had seen with reservations, because she took my questions in stride. Even with her reassurance, I couldnt shake the feeling that Id come out looking like Donatella Versace. But then, when she said we could start with less and add more, I said, Screw it. Im here, load my face up. Besides, it only lasts roughly 4-6 months. So, if I didnt like it, I figured I could just become a shut-in during the cold winter months. Not the end of the world.

First, she numbed my face. Then, she started poking me with a syringe and loading me up with various fillers. Ill admit, it hurt a bit more than I thought it would. However, you can take breaks and the pain shouldnt deter you if you want to get this type of work doneits not that bad.

She stuck me for about an hour, hitting almost every part of my face. Throughout, shed stop and show me what she was doing, asking if I wanted more. Sometimes I said yes, other times I said noespecially when she worked on my lips. I knew that big, plump lips would make me look like a clown and, personally, I just dont care for that fake lip look.

Finally, I was done. When I looked in the mirror, it was scary. My face was so numb that I could barely move it. There was also some blood and injections swell for a few days before going down, so I liked really puffy. But, I will say, the bump on my nose had vanished. It was absolutely bewildering and incredible. As someone who has been self-conscious about my nose for years, it was exhilarating to see a change so quickly.

The first two days after all the injections was hard. It was tough to eat because it hurt to clench my jaw. But each day the pain lessened and by day three, nearly everything had settled. By day five, I looked how I look nowand let me tell you, Im damn stunning. Most of my wrinkles are gone and my face is far more symmetrical than it was before. When I take a photo, my cheekbones hit the light and pop. And dont even get me started on my nose!

Heres the thing: Most folks cant even tell Ive gotten work done, which is what I hoped for. Some friends who have either gotten their own work done or who want to get some done could telland they gushed over the results. And, of course, a few friends say, Why did you do that? I loved how you looked. The answer is, I didnt do it for themI did it for me. I did it to feel more comfortable in my skin.

All in all, I dont see much downside in getting fillers. I loved itwhich means I am going to have to go back to Dr. Cheung every 4-6 months. I see it as a small price to pay for the confidence it gave me.

Like what you just read? Youll love our magazine! Go here to subscribe. Dont miss a thing by downloading Apple News here and following Prevention. Oh, and were on Instagram too.

Go here to see the original:
I Got Fillers to Fix the Bump on My Noseand It Was Bizarre and Incredible - Prevention.com

Posted in Regenerative Medicine | Comments Off on I Got Fillers to Fix the Bump on My Noseand It Was Bizarre and Incredible – Prevention.com

Page 51«..1020..50515253..6070..»